WFH-WebinarNowAvail-620x400-June2021-EN

WFH hears from FDA, EMA and WHO on COVID-19 vaccine safety for PWBD

On June 2, 2021, the World Federation of Hemophilia (WFH) held “COVID-19 Vaccines and People with Bleeding Disorders: Safety and Accessibility”, a webinar that addressed the concerns and needs of the global bleeding disorders community, allowing them to approach vaccination with greater confidence.

Also available in: Français Español

On June 2, 2021, the World Federation of Hemophilia (WFH) held “COVID-19 Vaccines and People with Bleeding Disorders: Safety and Accessibility”, a webinar that addressed the concerns and needs of the global bleeding disorders community, allowing them to approach vaccination with greater confidence.

Over 300 participants from 118 countries joined the event to listen to the presentations and participate in the Q&A period. The webinar featured speakers from a number of key organizations at the forefront of pandemic vaccination efforts, including the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and the World Health Organization (WHO). WFH experts were also on the panel in order to offers participants a complete set of recommendations for PWBD.

The event started with a presentation by Cedric Hermans, MD, PhD, WFH Medical board member (Belgium), who covered key issues in COVID-19 vaccines for PWBDs. The next two presentations—by Manuela Mura, PhD, Scientific Officer, European Medicines Agency (Netherlands) and Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA (U.S.A.)—focused on the authorization and safety of COVID-19 vaccines, with a focus on the regulators’ perspectives from the European Union and the U.S.A, respectively. The last presentation, by Claudia Nannei, Senior Technical Officer, WHO (Switzerland), reviewed new information on the COVAX initiative from the Coalition for Epidemic Preparedness Innovations (CEPI); Gavi, the Vaccine Alliance; and the WHO.

“With an impressive panel of speakers representing the FDA, EMA and the COVAX project in collaboration with the WHO, the webinar provided an update on the global access to COVID vaccines, as well as up-to-date information on the FDA and EMA safety and efficacy assessments of COVID vaccines. Vaccine distribution is greatly imbalanced between high income and low-income countries, yet if we don’t vaccinate everyone as rapidly as possible, we all risk [being exposed to] COVID variants that will prolong the pandemic everywhere.”
—Glenn Pierce, MD, PhD, Vice-President Medical, WFH

The presentations were followed by a dynamic question and answer period, which included the expertise of Glenn Pierce, MD, PhD, WFH Vice President, Medical (U.S.A); and Radoslaw F. Kaczmarek, PhD, WFH Coagulation Product Safety, Supply, and Access (CPSSA) Committee chair (Poland/U.S.A.) along with the other panel members.

If you missed the webinar, you can listen to it on the WFH eLearning Platform by clicking here. You can also watch the March 12, 2021 webinar—“COVID-19 Treatment and Vaccination for PWBDs”—by clicking here. To attend the other webinars that the WFH is organizing, you can consult our calendar of events here.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.